A natural product secreted by a soil bacterium may lead to a new drug to treat tuberculosis, report scientists in a new study.
Pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, has been shown to be active against many of the drug-resistant types of the tuberculosis bacterium that no longer respond to treatment with the front-line drug isoniazid.
Tuberculosis causes up to two million deaths annually and there is a significant need for new drugs since the effectiveness of current antibiotics is compromised by the increasing prevalence of drug-resistant tuberculosis. The most effective drugs used to treat tuberculosis, like isoniazid and rifampicin, are not always effective.
The researchers identified a protein, the enzyme NADH-dependent enoyl(acyl carrier protein) reductase or InhA, the principal target for the antibiotic. "By selecting and isolating M. tuberculosis mutants resistant to pyridomycin and sequencing their genome we have found that a single gene named inhA is responsible for resistance to this natural product," said Stewart Cole, lead author of the study and a professor at the École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.
The gene inhA is needed to produce the InhA protein, which is already known as a target for tuberculosis drug isoniazid. It turns out that pyridomycin can bind to the same pocket on the InhA enzyme as isoniazid but at a different site and in a way that involves a different sequence of molecular events. It is these differences that give pyridomycin the ability to overcome drug-resistant strains of mycobacteria.
"Nature and evolution have equipped some bacteria with potent defense mechanisms to protect them against other bugs that share their habitat. Screening natural products generated by these organisms is therefore a powerful way to find possible new drugs to fight infectious diseases," said Cole. "Using this approach we have shown that nature's antibiotic pyridomycin is a very selective killer of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis in humans. It is also active against mycobacteria that have developed resistance to front-line drug treatments such as isoniazid."
The scientists showed that in live bacteria treatment with pyridomycin leads to the depletion of mycolic acids, fatty acids that are an essential component of the bacterial cell wall.
"Our finding that pyridomycin kills Mycobacterium tuberculosis by inhibiting InhA, even in clinically isolated bacteria that are resistant to the drug isoniazid, provides a great opportunity to develop pyridomycin or a related agent for the treatment of drug-resistant tuberculosis," Cole said.
Published in EMBO Molecular Medicine.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Poisons Chemists Hate, But You Just Ate
- Our Ethical Responsibilities To Baby Terraformed Worlds - Like Parents
- Single Top Production At The LHC
- Supersymmetry Is About To Be Discovered, Kane Says
- Dietary Restriction, Circadian Rhythm, And Long Life
- Anomaly! - A Different Particle Physics Book
- New Open-access Data On Paleofloods
- "The reason I needed to do an article is because so many of you are so scared by it. I wouldn't..."
- "You have nothing to worry about or scared about by way of mythical bullshit planets :). I don't..."
- "Well it's not going to happen, and it's just so sad that so many of you are getting worked up about..."
- "Where is this article, out of interest?I'm not too surprised, that there'd be some reaction. After..."
- "some people are saying nibiru wont hit earth its just going to cause mayhem on our planet apparently..."
- Earth's first ecosystems were more complex than previously thought, study finds
- Soil pulled from deep under Oregon's unglaciated Coast Range unveils frosty past climate
- Mystery of how snakes lost their legs solved by reptile fossil
- Seizure risk of anti-shivering agent meperidine greatly overstated
- Immune-disorder treatment in mice holds potential for multiple sclerosis patients